Clinical trials: Cancer, Carcinoma
Non-Small Cell Lung Cancer
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC
- Trial name
- Genomet (NCT07613424)
- Testing
- NGS testing, MET IHC testing, PD-L1 and Her2 testing
- Where
- 51 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a chemotherapy and radiotherapy sensitive tumor, but with very high rates of relapse and metastasis, resulting in a very poor outcome.
- Trial name
- NCT01173523
- Testing
- STA-9090
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- David M. Jackman, MD
Colorectal Cancer, Breast Carcinoma
FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
This trial is a first in human (FIH) clinical trial in patients with Colorectal cancer (CRC) after failure of at least three lines of previous therapy aiming to evaluate safety and efficacy of CC-3, a bispecific antibody (bsAb)…
- Conditions
- Colorectal Cancer, Breast Carcinoma, Sarcoma, Penile Carcinoma
- Trial name
- CoRe_CC-3 (NCT05999396)
- Testing
- Administration of CC-3
- Where
- Germany
- Volunteers
- 89 people
- Sponsor
- German Cancer Research Center
Non-small Cell Lung Cancer
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01427946
- Testing
- IPI-504, Everolimus
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body, and protect your normal tissue.
- Trial name
- HUM15709 (NCT01190527)
- Testing
- FDG-PET
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan Rogel Cancer Center
Rectal Carcinoma, Surgery
COLOR III Trial: Transanal vs Laparoscopic TME
Background Surgery for mid and low rectal cancer is associated with relative high rates of incomplete mesorectal excisions and high rates of circumferential resection margin (CRM) involvement resulting in significant number of…
- Trial name
- COLORIII (NCT02736942)
- Testing
- Laparoscopic TME, TaTME
- Where
- Netherlands
- Volunteers
- 1,104 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma)
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received…
- Trial name
- MOMENT (NCT07592910)
- Testing
- Mevrometostat, Enzalutamide
- Volunteers
- 60 people
- Sponsor
- Prostate Cancer Clinical Trials Consortium
Thyroid Cancer
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds.
- Trial name
- NCT01496313
- Testing
- 300mg vandetanib, 150mg vandetanib
- Where
- 30 sites in United States, Czechia and 7 more
- Volunteers
- 81 people
- Sponsor
- Sanofi
Lung Cancer (NSCLC), Lung Cancer (SCLC)
Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung
This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.
- Trial name
- PRACTICAL (NCT07202260)
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- The Christie NHS Foundation Trust
Kidney Cancer
Contrast Ultrasound Dispersion Imaging (CUDI) as a Diagnostic Modality in the Diagnosis of Renal Cell Carcinoma
Introduction The current limitations of renal cell carcinoma (RCC) imaging form a major deficit in the diagnostic pathway. Contrast Enhanced UltraSound (CEUS) has the potential to improve RCC detection and localization…
- Trial name
- CUDI-RCC (NCT04669613)
- Testing
- CUDI
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.
- Trial name
- NCT00316420
- Testing
- Capecitabine (Xeloda), Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Parathyroid Carcinoma, Parathyroid Neoplasm
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Objectives: 1. Identify the clinical characteristics of parathyroid (PTH) cancer and PTH atypical neoplasms 2. Investigate if PTH carcinoma and atypical neoplasm present a biological behaviour and have a different impact on the…
- Trial name
- NCT03046524
- Testing
- Chart Review
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
A Study of Nivolumab in Patients With Head and Neck Cancer.
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
- Trial name
- ProNiHN (NCT04050761)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 502 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Intrahepatic Cholangiocarcinoma
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients…
- Conditions
- Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Neoplasms, PD-1 Inhibitor
- Trial name
- NCT05913661
- Testing
- Pemigatinib, PD-1 Inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Adenocarcinoma
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.
- Trial name
- NCT00892242
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult…
- Trial name
- NCT06862869
- Testing
- Alectinib
- Where
- 44 sites in China
- Volunteers
- 800 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.